Glaukos Toekomstige groei
Future criteriumcontroles 2/6
Glaukos zal naar verwachting groeien in winst en omzet met respectievelijk 65.4% en 20.3% per jaar. De winst per aandeel zal naar verwachting groeien met 67.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -4.6% zijn.
Belangrijke informatie
65.4%
Groei van de winst
67.9%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 17.0% |
| Inkomstengroei | 20.3% |
| Toekomstig rendement op eigen vermogen | -4.6% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 15 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Is Glaukos (NYSE:GKOS) Using Debt In A Risky Way?
Sep 18
Glaukos Corporation: Ripe For Some Consolidation
Sep 11Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 28Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 07Glaukos Corporation's (NYSE:GKOS) Popularity With Investors Is Clear
Jul 18Glaukos (NYSE:GKOS) Is Carrying A Fair Bit Of Debt
Jun 11Glaukos Stock: Still Unproven Whether A New Bull Market Has Begun
May 30Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns
May 24Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching
Apr 22Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing
Apr 04Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price
Feb 21Is Glaukos (NYSE:GKOS) A Risky Investment?
Jan 21Glaukos: Remains A Hold Due To High Valuation And Negative Profitability
Jan 09Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors
Dec 20Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching
Nov 03Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?
Oct 05Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support
Sep 01Is Glaukos (NYSE:GKOS) Using Debt Sensibly?
Jun 28Glaukos: Revising To Buy On These 3 Catalytic Factors
Jun 16Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)
Apr 19Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?
Feb 19Glaukos: Trial Momentum Building, Profitability Differentials Yet To Pull Through
Feb 14Glaukos sees positive data from mid-stage trial of dry eye treatment
Jan 10Glaukos: Show Me The Money
Nov 10Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?
Oct 16Glaukos pays $10M upfront to license iVeena's eye disorder therapy IVMED-80
Aug 24Glaukos: Gross Margins Compressing Despite FY22 Guidance Revision
Aug 04Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 594 | -34 | 106 | 123 | 12 |
| 12/31/2025 | 473 | -75 | 13 | 51 | 14 |
| 12/31/2024 | 378 | -141 | -36 | -20 | 14 |
| 9/30/2024 | 360 | -150 | -81 | -72 | N/A |
| 6/30/2024 | 342 | -159 | -82 | -71 | N/A |
| 3/31/2024 | 326 | -141 | -75 | -61 | N/A |
| 12/31/2023 | 315 | -135 | -78 | -58 | N/A |
| 9/30/2023 | 304 | -129 | -75 | -51 | N/A |
| 6/30/2023 | 297 | -126 | -97 | -70 | N/A |
| 3/31/2023 | 289 | -139 | -104 | -74 | N/A |
| 12/31/2022 | 283 | -99 | -63 | -33 | N/A |
| 9/30/2022 | 285 | -90 | -65 | -34 | N/A |
| 6/30/2022 | 288 | -56 | -25 | 11 | N/A |
| 3/31/2022 | 294 | -28 | -7 | 30 | N/A |
| 12/31/2021 | 294 | -50 | -23 | 25 | N/A |
| 9/30/2021 | 294 | -38 | -1 | 40 | N/A |
| 6/30/2021 | 284 | -60 | -19 | 13 | N/A |
| 3/31/2021 | 238 | -83 | -29 | -6 | N/A |
| 12/31/2020 | 225 | -120 | -30 | -23 | N/A |
| 9/30/2020 | 218 | -73 | -44 | -38 | N/A |
| 6/30/2020 | 211 | -71 | -37 | -31 | N/A |
| 3/31/2020 | 238 | -37 | -19 | -14 | N/A |
| 12/31/2019 | 237 | 15 | -5 | 0 | N/A |
| 9/30/2019 | 225 | -19 | 10 | 21 | N/A |
| 6/30/2019 | 211 | -12 | 17 | 28 | N/A |
| 3/31/2019 | 195 | -12 | 16 | 26 | N/A |
| 12/31/2018 | 181 | -13 | 9 | 19 | N/A |
| 9/30/2018 | 169 | -14 | 10 | 14 | N/A |
| 6/30/2018 | 165 | -6 | N/A | 17 | N/A |
| 3/31/2018 | 163 | -4 | N/A | 17 | N/A |
| 12/31/2017 | 159 | 0 | N/A | 26 | N/A |
| 9/30/2017 | 151 | -1 | N/A | 17 | N/A |
| 6/30/2017 | 140 | -1 | N/A | 14 | N/A |
| 3/31/2017 | 127 | 5 | N/A | 16 | N/A |
| 12/31/2016 | 114 | 5 | N/A | 12 | N/A |
| 9/30/2016 | 102 | 2 | N/A | 8 | N/A |
| 6/30/2016 | 91 | -1 | N/A | 4 | N/A |
| 3/31/2016 | 80 | -35 | N/A | -2 | N/A |
| 12/31/2015 | 72 | -37 | N/A | -2 | N/A |
| 9/30/2015 | 66 | -40 | N/A | -3 | N/A |
| 6/30/2015 | 59 | -39 | N/A | -2 | N/A |
| 3/31/2015 | 52 | -9 | N/A | -3 | N/A |
| 12/31/2014 | 46 | -12 | N/A | -7 | N/A |
| 9/30/2014 | 38 | -11 | N/A | -8 | N/A |
| 6/30/2014 | 33 | -12 | N/A | -10 | N/A |
| 3/31/2014 | 26 | -13 | N/A | -13 | N/A |
| 12/31/2013 | 21 | -13 | N/A | -13 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat GKOS de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat GKOS de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat GKOS de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van GKOS ( 20.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).
Hoge groei-inkomsten: De omzet van GKOS ( 20.3% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat GKOS binnen 3 jaar verliesgevend zal zijn.